Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) — Market Cap & Net Worth
Market Cap & Net Worth: Ind-Swift Laboratories Limited (INDSWFTLAB)
Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) has a market capitalization of $350.52 Million (Rs32.41 Billion) as of September 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #14207 globally and #703 in its home market, demonstrating a -3.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ind-Swift Laboratories Limited's stock price Rs373.25 by its total outstanding shares 86836558 (86.84 Million). Also see INDSWFTLAB current and non-current assets for a full breakdown of the balance sheet.
Ind-Swift Laboratories Limited Market Cap History: 2015 to 2026
Ind-Swift Laboratories Limited's market capitalization history from 2015 to 2026. Data shows growth from $34.84 Million to $350.52 Million (24.03% CAGR). Also see Ind-Swift Laboratories Limited cash conversion from operations for how efficiently the company converts equity into cash flow.
Ind-Swift Laboratories Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ind-Swift Laboratories Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check INDSWFTLAB live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
Ind-Swift Laboratories Limited's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.03x
Ind-Swift Laboratories Limited's market cap is 0.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $34.00 Million | $6.53 Billion | -$586.88 Million | 0.01x | N/A |
| 2017 | $71.94 Million | $6.97 Billion | -$391.34 Million | 0.01x | N/A |
| 2018 | $45.69 Million | $7.65 Billion | $219.76 Million | 0.01x | 0.21x |
| 2019 | $21.98 Million | $7.57 Billion | $289.46 Million | 0.00x | 0.08x |
| 2020 | $58.46 Million | $7.80 Billion | -$211.88 Million | 0.01x | N/A |
| 2021 | $63.81 Million | $8.91 Billion | -$31.47 Million | 0.01x | N/A |
| 2022 | $65.22 Million | $10.39 Billion | -$21.49 Million | 0.01x | N/A |
| 2023 | $97.24 Million | $12.07 Billion | $475.97 Million | 0.01x | 0.20x |
| 2024 | $101.96 Million | $12.81 Billion | $4.21 Billion | 0.01x | 0.02x |
| 2025 | $82.78 Million | $5.62 Billion | $2.50 Billion | 0.01x | 0.03x |
Competitor Companies of INDSWFTLAB by Market Capitalization
Companies near Ind-Swift Laboratories Limited in the global market cap rankings as of September 19, 2026. Review INDSWFTLAB tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Ind-Swift Laboratories Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Ind-Swift Laboratories Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Ind-Swift Laboratories Limited's market cap moved from $34.84 Million to $ 350.52 Million, with a yearly change of 24.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs350.52 Million | +323.43% |
| 2025 | Rs82.78 Million | -18.81% |
| 2024 | Rs101.96 Million | +4.85% |
| 2023 | Rs97.24 Million | +49.10% |
| 2022 | Rs65.22 Million | +2.21% |
| 2021 | Rs63.81 Million | +9.16% |
| 2020 | Rs58.46 Million | +166.03% |
| 2019 | Rs21.98 Million | -51.90% |
| 2018 | Rs45.69 Million | -36.49% |
| 2017 | Rs71.94 Million | +111.60% |
| 2016 | Rs34.00 Million | -2.43% |
| 2015 | Rs34.84 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Ind-Swift Laboratories Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $350.52 Million USD |
| MoneyControl | $350.52 Million USD |
| MarketWatch | $350.52 Million USD |
| marketcap.company | $350.52 Million USD |
| Reuters | $350.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more